Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus

BACKGROUND: The Epstein-Barr virus (EBV) viral glycoprotein gp350 has been proposed as a candidate antigen for an EBV vaccine. However, the proposed formulations of these vaccines have not taken into account the presence of 2 unique EBV strains (EBV-1 and EBV-2) present in areas of high incidence of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Infect Dis
Auteurs principaux: Smith, Nicholas A, Baresel, Paul C, Jackson, Conner L, Ogolla, Sidney, Toko, Eunice N, Heit, Sara, Piriou, Erwan, Sumba, Odada P, Middeldorp, Jaap M, Colborn, Kathryn L, Rochford, Rosemary
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Major Articles and Brief Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6386812/
https://ncbi.nlm.nih.gov/pubmed/30312417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy601
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires